Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 5 | 2025 | 25 | 1.250 |
Why?
|
| African Americans | 8 | 2016 | 264 | 0.820 |
Why?
|
| Community-Based Participatory Research | 6 | 2024 | 51 | 0.770 |
Why?
|
| Humans | 40 | 2025 | 6794 | 0.750 |
Why?
|
| Neoplasms | 5 | 2015 | 92 | 0.730 |
Why?
|
| Community Health Services | 4 | 2017 | 35 | 0.680 |
Why?
|
| Poverty | 3 | 2016 | 64 | 0.640 |
Why?
|
| Female | 26 | 2025 | 4060 | 0.600 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2020 | 2 | 0.590 |
Why?
|
| Community-Institutional Relations | 3 | 2017 | 21 | 0.560 |
Why?
|
| Middle Aged | 21 | 2025 | 2108 | 0.550 |
Why?
|
| Aged | 18 | 2025 | 1539 | 0.520 |
Why?
|
| Medically Uninsured | 2 | 2016 | 11 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2015 | 153 | 0.490 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2016 | 4 | 0.480 |
Why?
|
| Patient Navigation | 1 | 2016 | 7 | 0.480 |
Why?
|
| Adult | 18 | 2025 | 2113 | 0.470 |
Why?
|
| Health Status Disparities | 4 | 2015 | 83 | 0.440 |
Why?
|
| Albuminuria | 2 | 2012 | 31 | 0.440 |
Why?
|
| Cooperative Behavior | 3 | 2014 | 28 | 0.430 |
Why?
|
| Lymph Nodes | 1 | 2014 | 9 | 0.420 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 293 | 0.420 |
Why?
|
| Myometrium | 1 | 2014 | 11 | 0.420 |
Why?
|
| Urban Health Services | 1 | 2014 | 17 | 0.410 |
Why?
|
| Peritoneal Neoplasms | 2 | 2024 | 3 | 0.410 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 35 | 0.400 |
Why?
|
| Male | 20 | 2020 | 3671 | 0.400 |
Why?
|
| Los Angeles | 9 | 2023 | 321 | 0.350 |
Why?
|
| Mass Screening | 1 | 2012 | 116 | 0.350 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 170 | 0.340 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 59 | 0.290 |
Why?
|
| Quality of Health Care | 1 | 2008 | 27 | 0.280 |
Why?
|
| Organizational Case Studies | 1 | 2008 | 1 | 0.280 |
Why?
|
| Health Education | 1 | 2008 | 55 | 0.270 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 5 | 0.260 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 420 | 0.260 |
Why?
|
| Social Welfare | 1 | 2006 | 2 | 0.250 |
Why?
|
| Patient Care Management | 1 | 2006 | 4 | 0.250 |
Why?
|
| Interdisciplinary Communication | 1 | 2006 | 7 | 0.250 |
Why?
|
| Prognosis | 5 | 2025 | 220 | 0.250 |
Why?
|
| Peritoneum | 1 | 2025 | 4 | 0.230 |
Why?
|
| Medicaid | 2 | 2007 | 19 | 0.230 |
Why?
|
| Immunotherapy | 1 | 2025 | 16 | 0.230 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 172 | 0.230 |
Why?
|
| DNA Mismatch Repair | 2 | 2025 | 5 | 0.220 |
Why?
|
| Health Services | 1 | 2004 | 12 | 0.220 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2024 | 1 | 0.220 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 29 | 0.220 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 208 | 0.220 |
Why?
|
| Clinical Medicine | 1 | 2004 | 2 | 0.210 |
Why?
|
| Health Services Research | 1 | 2004 | 27 | 0.210 |
Why?
|
| Drinking Water | 1 | 2023 | 5 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 279 | 0.200 |
Why?
|
| Adolescent | 7 | 2020 | 869 | 0.200 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2022 | 2 | 0.190 |
Why?
|
| United States | 6 | 2025 | 1019 | 0.190 |
Why?
|
| Residence Characteristics | 2 | 2016 | 36 | 0.190 |
Why?
|
| Telemedicine | 1 | 2023 | 43 | 0.190 |
Why?
|
| Insurance Coverage | 2 | 2016 | 14 | 0.180 |
Why?
|
| Vaccines | 1 | 2022 | 10 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2019 | 197 | 0.180 |
Why?
|
| HIV Infections | 1 | 2006 | 432 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 54 | 0.170 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 5 | 0.170 |
Why?
|
| Chagas Disease | 1 | 2020 | 4 | 0.160 |
Why?
|
| Antibodies, Protozoan | 1 | 2020 | 8 | 0.160 |
Why?
|
| Medical Record Linkage | 1 | 2019 | 6 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 5 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2025 | 45 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2019 | 34 | 0.150 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 497 | 0.150 |
Why?
|
| Qualitative Research | 2 | 2017 | 82 | 0.150 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 10 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 13 | 0.150 |
Why?
|
| Risk Factors | 5 | 2020 | 767 | 0.150 |
Why?
|
| Young Adult | 6 | 2020 | 567 | 0.150 |
Why?
|
| Developing Countries | 2 | 2009 | 38 | 0.140 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 83 | 0.140 |
Why?
|
| Health Behavior | 3 | 2015 | 65 | 0.140 |
Why?
|
| Community Health Workers | 2 | 2008 | 13 | 0.130 |
Why?
|
| Perception | 2 | 2015 | 19 | 0.130 |
Why?
|
| Allostasis | 1 | 2017 | 6 | 0.130 |
Why?
|
| Religion | 1 | 2017 | 16 | 0.130 |
Why?
|
| Safety-net Providers | 1 | 2017 | 24 | 0.130 |
Why?
|
| Mortality | 1 | 2017 | 43 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 35 | 0.130 |
Why?
|
| Health Promotion | 1 | 2017 | 89 | 0.120 |
Why?
|
| Hypertension | 3 | 2019 | 147 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2020 | 681 | 0.120 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 506 | 0.120 |
Why?
|
| Chicago | 1 | 2016 | 8 | 0.120 |
Why?
|
| Research Subjects | 1 | 2015 | 7 | 0.110 |
Why?
|
| Disease-Free Survival | 2 | 2025 | 24 | 0.110 |
Why?
|
| Health Status | 1 | 2016 | 83 | 0.110 |
Why?
|
| Patient Selection | 1 | 2015 | 40 | 0.110 |
Why?
|
| Trust | 1 | 2015 | 33 | 0.110 |
Why?
|
| Age Factors | 4 | 2020 | 193 | 0.110 |
Why?
|
| Feeding Behavior | 2 | 2012 | 38 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2016 | 167 | 0.110 |
Why?
|
| Registries | 3 | 2020 | 63 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 8 | 0.110 |
Why?
|
| SEER Program | 1 | 2014 | 9 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 19 | 0.100 |
Why?
|
| Risk | 1 | 2014 | 43 | 0.100 |
Why?
|
| Delphi Technique | 1 | 2014 | 16 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 34 | 0.100 |
Why?
|
| Universities | 1 | 2014 | 21 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2014 | 34 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2014 | 60 | 0.100 |
Why?
|
| San Francisco | 2 | 2023 | 13 | 0.100 |
Why?
|
| Pandemics | 2 | 2024 | 87 | 0.090 |
Why?
|
| Internet | 1 | 2012 | 25 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2025 | 331 | 0.090 |
Why?
|
| Nutrition Assessment | 1 | 2012 | 26 | 0.090 |
Why?
|
| Mortality, Premature | 1 | 2011 | 4 | 0.090 |
Why?
|
| Acute Kidney Injury | 2 | 2009 | 27 | 0.090 |
Why?
|
| Fatigue | 1 | 2011 | 7 | 0.090 |
Why?
|
| Acupuncture Therapy | 1 | 2011 | 4 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 197 | 0.090 |
Why?
|
| Self Care | 1 | 2011 | 23 | 0.090 |
Why?
|
| Violence | 1 | 2011 | 52 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 58 | 0.080 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 45 | 0.080 |
Why?
|
| Health Surveys | 2 | 2008 | 75 | 0.080 |
Why?
|
| Zoonoses | 1 | 2009 | 2 | 0.070 |
Why?
|
| Leptospirosis | 1 | 2009 | 2 | 0.070 |
Why?
|
| Snake Bites | 1 | 2009 | 9 | 0.070 |
Why?
|
| Case Management | 1 | 2008 | 6 | 0.070 |
Why?
|
| Creatinine | 1 | 2008 | 48 | 0.070 |
Why?
|
| Food Supply | 1 | 2008 | 11 | 0.070 |
Why?
|
| Education | 1 | 2008 | 11 | 0.070 |
Why?
|
| Consensus | 1 | 2008 | 39 | 0.070 |
Why?
|
| Prevalence | 3 | 2019 | 259 | 0.070 |
Why?
|
| Public Health | 1 | 2008 | 40 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2015 | 145 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2007 | 5 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2007 | 26 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 56 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 65 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2025 | 2 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2025 | 13 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 23 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 21 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 51 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2025 | 2 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 1 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2024 | 10 | 0.050 |
Why?
|
| Capital Financing | 1 | 2004 | 1 | 0.050 |
Why?
|
| Risk-Taking | 2 | 2015 | 77 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 11 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2004 | 9 | 0.050 |
Why?
|
| Forecasting | 1 | 2004 | 19 | 0.050 |
Why?
|
| Teaching | 1 | 2004 | 13 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2004 | 10 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 280 | 0.050 |
Why?
|
| Taxes | 1 | 2023 | 2 | 0.050 |
Why?
|
| Water Supply | 1 | 2023 | 6 | 0.050 |
Why?
|
| Cities | 1 | 2023 | 7 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 14 | 0.050 |
Why?
|
| Vaccination | 1 | 2022 | 49 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2020 | 4 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2020 | 12 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 45 | 0.040 |
Why?
|
| Endometrium | 1 | 2020 | 24 | 0.040 |
Why?
|
| Diet | 2 | 2012 | 111 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 26 | 0.040 |
Why?
|
| Bolivia | 1 | 2020 | 1 | 0.040 |
Why?
|
| Trypanosoma cruzi | 1 | 2020 | 4 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 10 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 97 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 35 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 16 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 187 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2019 | 31 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2020 | 258 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 170 | 0.040 |
Why?
|
| Causality | 2 | 2009 | 8 | 0.040 |
Why?
|
| Brazil | 2 | 2009 | 15 | 0.040 |
Why?
|
| Comorbidity | 2 | 2009 | 147 | 0.040 |
Why?
|
| Child | 1 | 2020 | 524 | 0.030 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 4 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 42 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 28 | 0.030 |
Why?
|
| Algorithms | 1 | 2017 | 83 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 82 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2009 | 500 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 169 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2016 | 8 | 0.030 |
Why?
|
| Environment Design | 1 | 2016 | 4 | 0.030 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 3 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 16 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 23 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2015 | 61 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 111 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 92 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2015 | 285 | 0.030 |
Why?
|
| Animals | 2 | 2009 | 1875 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 19 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 46 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 89 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2012 | 48 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 49 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2011 | 1 | 0.020 |
Why?
|
| Relaxation Therapy | 1 | 2011 | 1 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Integrative Medicine | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2011 | 19 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 44 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 67 | 0.020 |
Why?
|
| Castration | 1 | 2010 | 13 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 55 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 22 | 0.020 |
Why?
|
| Austria | 1 | 2010 | 2 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 77 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 268 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 155 | 0.020 |
Why?
|
| Bothrops | 1 | 2009 | 1 | 0.020 |
Why?
|
| Penicillins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 4 | 0.020 |
Why?
|
| Crotalus | 1 | 2009 | 4 | 0.020 |
Why?
|
| Doxycycline | 1 | 2009 | 4 | 0.020 |
Why?
|
| Antivenins | 1 | 2009 | 9 | 0.020 |
Why?
|
| Urban Health | 1 | 2009 | 20 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 7 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 82 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 84 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 10 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2008 | 11 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 73 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 66 | 0.020 |
Why?
|
| Biomarkers | 1 | 2008 | 214 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 11 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2007 | 82 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 67 | 0.020 |
Why?
|
| Social Class | 1 | 2007 | 46 | 0.020 |
Why?
|
| Medicare | 1 | 2007 | 57 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 56 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 104 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2006 | 121 | 0.010 |
Why?
|